MARCO Antibody (2359A) [Alexa Fluor® 647]

• Reactivity: Mu
• Applications: Flow
• Clone: 2359A
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Alexa Fluor 647

MARCO Antibody (2359A) [Alexa Fluor® 647] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Mouse myeloma cell line, NS0-derived mouse MARCO protein
  Gln70-Ser518
  Accession # Q60754
• Specificity: Detects mouse MARCO in direct ELISAs.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25-1 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for MARCO Antibody (2359A) [Alexa Fluor® 647]

• macrophage receptor with collagenous structureSCARA2Scavenger receptor class A member 2
• MARCO
• member 2
• SCARA2

Background

MARCO (macrophage receptor with collagenous structure), also known as SCARA2, is an 80 kDa type II transmembrane glycoprotein that belongs to the class A scavenger receptor family (1). Mouse MARCO consists of a 48 amino acid (aa) cytoplasmic domain, a 21 aa transmembrane segment, and a 449 aa extracellular domain (ECD) that includes a stalk region, a collagen-like region, and one SRCR domain (2). Within the ECD, mouse MARCO shares 69% and 86% aa sequence identity with human and rat MARCO, respectively. It shares 18%-28% aa sequence identity with other mouse class A scavenger receptors CL-P1, SCARA3, SCARA5, and SR-A1/MSR. MARCO is constitutively expressed on the surface of splenic and lymph node macrophages (2, 3). Its expression is induced on Kupffer cells and alveolar macrophages by microbial infection, chemical irritants, and Th1 polarizing factors (3-5). MARCO binds LPS, lipoteichoic acid, and other determinants on Gram positive and Gram negative bacteria (2, 6-8). It also binds modified LDL, CpG oligonucleotides, UGRP1, silica, and TiO₂ (2, 9-11). MARCO is required for the organization of the splenic marginal zone and the interaction of local macrophages and B cells (12, 13). The SRCR domain mediates binding of MARCO to its various ligands (3, 12), while the collagen-like region mediates assembly into a disulfide-linked trimeric molecule (2, 7). MARCO ligation induces, but is not required for the production of IL-12, NO, or TNF-alpha by macrophages (5, 6, 9). MARCO knockout mice show a reduced clearance of bacterial infections, reduced mast cell mediated silicosis, increased pulmonary inflammation, and increased sensitivity to ozone induced lung damage (4, 9, 14-16).

1. Murphy, J.E. et al. (2005) Atherosclerosis 182:1.
2. Elomaa, O. et al. (1995) Cell 80:603.
3. Van der Laan, L.J.W. et al. (1999) J. Immunol. 162:939.
4. Dahl, M. et al. (2007) J. Clin. Invest. 117:757.
5. Jozefowski, S. et al. (2005) J. Immunol. 175:8032. 
6. Mukhopadhyay, S. et al. (2006) Eur. J. Immunol. 36:940. 
7. Sankala, M. et al. (2002) J. Biol. Chem. 277:33378. 
8. Chen, Y. et al. (2006) J. Biol. Chem. 281:12767. 
9. Jozefowski, S. et al. (2006) J. Leukoc. Biol. 80:870.
10. Bin, L.-H. et al. (2003) J. Immunol. 171:924.
11. Hamilton, Jr. R.F. et al. (2006) J. Biol. Chem. 281:34218.
12. Karlsson, M.C.I. et al. (2003) J. Exp. Med. 198:333.
13. Chen, Y. et al. (2005) J. Immunol. 175:8173.
14. Arredouani, M. et al. (2004) J. Exp. Med. 200:267.
15. Arredouani, M.S. et al. (2007) J. Immunol. 178:5912.
16. Brown, J.M. et al. (2007) Am. J. Respir. Cell Mol. Biol. 36:43.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for MARCO Antibody (FAB29561R)(3)

Publications using FAB29561R

• Bresesti, C;Carito, E;Notaro, M;Giacca, G;Breggion, S;Kerzel, T;Mercado, CM;Beretta, S;Monti, M;Merelli, I;Canu, T;Naldini, L;Squadrito, ML; Reprogramming liver metastasis-associated macrophages toward an anti-tumoral phenotype through enforced miR-342 expression Cell reports 2025-04-19 [PMID: 40253698] (Flow Cytometry, Mouse)
• Caldwell, BA;Ie, S;Lucas, A;Li, L; Ticam2 ablation facilitates monocyte exhaustion recovery after sepsis Scientific reports 2025-01-15 [PMID: 39814939] (Flow Cytometry, Mouse)
• Wang, Y;Deng, W;Lee, D;Yan, L;Lu, Y;Dong, S;Huntoon, K;Antony, A;Li, X;Ye, R;Zhao, Y;Zhao, F;Schrank, BR;Ha, J;Kang, M;Yang, M;Gong, P;Lorenzi, PL;Tan, L;Gallup, TD;Tang, SK;Yang, Z;Li, J;Sanford, NN;Wang, H;Kim, BYS;Jiang, W; Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics Nature nanotechnology 2023-09-18 [PMID: 37723279] (IHC, Mouse)

Bioinformatics

• Uniprot:
  • Q60754()